Senior Architect – Serialization/Automation System at Acadia Pharmaceuticals

Lisbon, Lisbon, Portugal

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

PharmaceuticalsIndustries

Requirements

Master’s degree in Automation, Electrical, Computer, or Process Engineering
Minimum 8–10 years of experience in automation, serialization, or manufacturing IT systems in a regulated pharmaceutical environment
Strong knowledge of GAMP 5, GMP, CFR Part 11, and data integrity principles
Proven experience with serialization platforms (e.g., Antares Vision, Systech, SEA Vision) and integration with MES, ERP, and L4/L5 systems
Strong leadership and communication skills with experience leading cross-functional and global initiatives
Fluent in English; other languages are an asset

Responsibilities

Design and maintain global serialization and automation system architecture, ensuring compliance, scalability, and alignment with IT and manufacturing strategies
Develop standardized, efficient, and compliant shop-floor solutions that meet the needs of a regulated pharmaceutical environment
Lead global implementation and lifecycle management of serialization and automation platforms, ensuring delivery on time, within budget, and to quality standards
Collaborate with Global IT, Quality, and Operations teams, as well as external suppliers, to ensure harmonized processes and continuous system improvement
Ensure compliance with GMP, GAMP, and data integrity requirements while supporting audits, validations, and change controls
Drive innovation by identifying emerging technologies and promoting standardization, simplification, and digital transformation across sites

Skills

Serialization Systems

Automation Systems

System Architecture

GMP Compliance

GAMP

Data Integrity

Shop-Floor Solutions

Lifecycle Management

IT Strategy

Manufacturing Systems

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters

1993Year Founded

$813.4MTotal Funding

ACQUISITIONCompany Stage

Biotechnology, HealthcareIndustries

501-1,000Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.

Potential clinical trial delays could affect drug approval timelines.

Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.

The company has a strong R&D foundation, developing innovative small molecule drugs.

Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.

Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.

The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI

Try Jobo Free